The primary objective is to evaluate the efficacy of rosuvastatin therapy on plasma lipid profile (Low Density Lipoprotein (LDL), High-Density Lipoprotein (HDL), total cholesterol, triglyceride) in patients with metabolic syndrome.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Basal HDL-cholesterol Level
Timeframe: Baseline
HDL-cholesterol Level After 3 Months of Rosuvastatin Treatment
Timeframe: 3 months (from enrollment to last visit)
Basal LDL-cholesterol Level
Timeframe: Baseline
LDL-cholesterol Level After 3 Months of Rosuvastatin Treatment
Timeframe: 3 months (from enrollment to last visit)
Basal Total Cholesterol Level
Timeframe: Total cholesterol levels before (mean of visit 1 - screening and Visit 2 - enrollment)
Total Cholesterol Level After 3 Months of Rosuvastatin Treatment
Timeframe: 3 months (from enrollment to last visit)
Basal Triglyceride Level
Timeframe: Baseline
Triglyceride Level After 3 Months of Rosuvastatin Treatment
Timeframe: 3 months (from enrollment to last visit)
Number of Patients Who Reached Target Level of LDL-cholesterol After 3 Months of Rosuvastatin Treatment
Timeframe: 3 months (from enrollment to last visit)
Number of Patients Who Reached Target Level of HDL-cholesterol After 3 Months of Rosuvastatin Treatment
Timeframe: 3 months (from enrollment to last visit)
Number of Patients Who Reached Target Level of Non-HDL-cholesterol After 3 Months of Rosuvastatin Treatment
Timeframe: 3 months (from enrollment to last visit)